MAIN STORY
A negotiated outcome, not a finding of guilt
On October 14, the European Commission announced that it had accepted remedies offered by Sanofi to resolve competition concerns about influenza-vaccine communications. This is a commitments decision: obligations can be enforced, but the decision does not itself establish that the company infringed competition rules.
The formal inquiry began in June 2026 and focused on promotional messages delivered to healthcare professionals in France and Germany. Regulators suspected that descriptions of CSL Seqirus's Fluad could undermine confidence in a competitor while benefiting Sanofi's Efluelda. Sanofi had previously maintained that its conduct complied with applicable law.
According to Reuters, an infringement case could potentially have resulted in a fine of as much as 10% of Sanofi's annual worldwide turnover. By offering changes, the company redirected the process from a prolonged dispute over liability toward measurable conduct obligations.
What Sanofi has promised in two markets
For 24 months, Sanofi will publish clarifying notices on its German and French websites. In Germany, the notice addresses STIKO's assessment that Fluad and Efluelda each have a robust evidence base and can both be recommended.

















